DHR

AI Research

~$10B Masimo acquisition announced → DHR biotech diagnostics expansion

Danaher announced a approximately $10 billion acquisition of Masimo Corporation, expanding its life sciences diagnostics portfolio with medical monitoring technology used in hospitals worldwide. The deal is expected to be accretive to adjusted EPS within the first full year and strengthens Danaher's position in continuous patient monitoring. Analysts rate DHR a Strong Buy with an average price target of $264, though integration complexity and Masimo's prior proxy battle history add execution risk.